Full access
Clinical Synthesis
Published Online: 25 January 2022

Noninvasive Delivery of Biologicals to the Brain

Sheldon Jordan, M.D., F.A.A.N. [email protected], Margaret Zielinski, B.S., Marcin Kortylewski, Ph.D., Taylor Kuhn, Ph.D., and Alexander Bystritsky, M.D., Ph.D.Authors Info & Affiliations
Publication: FOCUS
Volume 20, Number 1
https://doi.org/10.1176/appi.focus.20210028
CME
PDF/EPUBformats

Abstract

In the past, psychotherapy and neuropharmacological approaches have been the most common treatments for disordered thoughts, moods, and behaviors. One new path of brain therapeutics is in the deployment of noninvasive approaches designed to reprogram brain function at the cellular level. Treatment at the cellular level may be considered for a wide array of disorders, ranging from mood disorders to neurodegenerative disorders. Brain-targeted biological therapy may provide minimally invasive and accurate delivery of treatment. The present article discusses the hurdles and advances that characterize the pathway to this goal.

Formats available

You can view the full content in the following formats:

View PDF/ePubView Full Text

Information & Authors

Information

Published In

Go to Focus
Go to Focus
FOCUS
Volume 20 • Number 1 • Winter 2022
Pages: 64 - 70

History

Published in print: Winter 2022
Published online: 25 January 2022

Keywords

  1. non-invasive
  2. brain-targeted
  3. biological therapy
  4. Neuroimaging - PS0398
  5. Pharmacokinetics - AJP0064

Authors

Affiliations

Sheldon Jordan, M.D., F.A.A.N. [email protected]
Department of Neurology, University of California, Los Angeles and Department of Neurology, University of Southern California, Los Angeles (Jordan);Neurological Associates—The Interventional Group, Los Angeles (Jordan, Zielinski);Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Los Angeles (Kortylewski);Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Kuhn, Bystritsky).
View all articles by this author
Margaret Zielinski, B.S.
Department of Neurology, University of California, Los Angeles and Department of Neurology, University of Southern California, Los Angeles (Jordan);Neurological Associates—The Interventional Group, Los Angeles (Jordan, Zielinski);Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Los Angeles (Kortylewski);Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Kuhn, Bystritsky).
View all articles by this author
Marcin Kortylewski, Ph.D.
Department of Neurology, University of California, Los Angeles and Department of Neurology, University of Southern California, Los Angeles (Jordan);Neurological Associates—The Interventional Group, Los Angeles (Jordan, Zielinski);Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Los Angeles (Kortylewski);Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Kuhn, Bystritsky).
View all articles by this author
Taylor Kuhn, Ph.D.
Department of Neurology, University of California, Los Angeles and Department of Neurology, University of Southern California, Los Angeles (Jordan);Neurological Associates—The Interventional Group, Los Angeles (Jordan, Zielinski);Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Los Angeles (Kortylewski);Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Kuhn, Bystritsky).
View all articles by this author
Alexander Bystritsky, M.D., Ph.D.
Department of Neurology, University of California, Los Angeles and Department of Neurology, University of Southern California, Los Angeles (Jordan);Neurological Associates—The Interventional Group, Los Angeles (Jordan, Zielinski);Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Los Angeles (Kortylewski);Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Kuhn, Bystritsky).
View all articles by this author

Notes

Send correspondence to Dr. Jordan ([email protected]).

Competing Interests

Dr. Jordan reports owning a focused ultrasound device and a transcranial magnetic stimulation device that may be used in some of the research discussed. Dr. Jordan also reports being part owner and member of the board of Synaptic Research, which performs research on focused ultrasound delivery of substances to the brain.

Competing Interests

Dr. Kortylewski reports serving on the Scientific Advisory Board of Scopus BioPharma and its subsidiary Duet Therapeutics. Dr. Bystritsky reports being chief executive officer of BrainSonix Corp., president of Westside Neurotherapeutics, president of the Institute for Advanced Consciousness Studies, a partner at CalNeuro Research Group, president of the Pacific Institute for Medical Research, and a partner and board member of Synaptic Research. The other authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Item saved, go to cart
Purchase Options

Purchase this article to access the full text.

PPV Articles - Focus

PPV Articles - Focus

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.